Nivolumab + Ipilimumab

Phase 2Terminated

0 views this week 0 watching💤 Quiet

Interest: 27/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Acral Lentiginous Melanoma

Conditions

Acral Lentiginous Melanoma, Mucosal Melanoma

Trial Timeline

Jul 26, 2017 → Aug 2, 2022

NCT ID

NCT02978443

About Nivolumab + Ipilimumab

Nivolumab + Ipilimumab is a phase 2 stage product being developed by Bristol Myers Squibb for Acral Lentiginous Melanoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT02978443. Target conditions include Acral Lentiginous Melanoma, Mucosal Melanoma.

What happened to similar drugs?

0 of 2 similar drugs in Acral Lentiginous Melanoma were approved

Approved (0) Terminated (1) Active (1)

❌IBI310+IBI308 + IBI308 + High-dose recombinant interferon a-2BInnovent BiologicsPhase 3

🔄SP-102 + PlaceboScilex HoldingPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02186249	Pre-clinical	Completed	—	—	Malignant Melanoma
NCT07024862	Pre-clinical	Active	Oct 24, 2024	Jun 30, 2025	Metastatic Non-small Cell Lung Cancer
NCT06487156	Pre-clinical	Active	Oct 11, 2023	Oct 11, 2030	Non-small Cell Lung Cancer (NSCLC)
NCT05219435	Phase 2	Active	Jul 6, 2022	Dec 1, 2025	Urothelial Cancer
NCT05302921	Phase 2	Completed	Feb 18, 2022	Mar 12, 2024	Osteosarcoma
NCT05088889	Phase 1	UNKNOWN	Jan 25, 2022	Jul 1, 2024	Stage IV Pancreatic Cancer
NCT04966676	Phase 2	Terminated	Jan 24, 2022	Feb 19, 2025	Non Small Cell Lung Cancer
NCT05215470	Phase 2	Active	Jan 18, 2022	Nov 30, 2026	Renal Cancer Metastatic
NCT04465643	Phase 1	Completed	Jun 8, 2021	Jul 30, 2025	Nerve Sheath Tumors
NCT04938232	Phase 2	Active	Jun 4, 2021	Aug 1, 2026	Hodgkin Lymphoma
NCT04495010	Phase 2	Withdrawn	Mar 31, 2021	Oct 23, 2027	Melanoma
NCT04513522	Approved	Completed	Dec 17, 2020	Jan 4, 2024	Kidney Neoplasms
NCT04434560	Phase 2	Terminated	Nov 4, 2020	Jun 17, 2021	Brain Metastases, Adult
NCT04575922	Phase 2	UNKNOWN	Oct 5, 2020	Jun 1, 2024	Metastatic Microsatellite Stable Colorectal Cancer
NCT04340193	Phase 3	Completed	Sep 14, 2020	Dec 12, 2023	Cancer, Hepatocellular
NCT04088500	Phase 2	Terminated	Sep 3, 2020	Nov 15, 2021	Renal Cell Carcinoma
NCT04361162	Phase 2	Active	May 18, 2020	Oct 1, 2026	Pancreatic Cancer
NCT03873402	Phase 3	Active	Jun 21, 2019	Mar 11, 2027	Renal Cell Carcinoma
NCT03461952	Phase 2	Terminated	Mar 11, 2019	Feb 9, 2022	Advanced Solid Tumors
NCT03789110	Phase 2	Active	Mar 8, 2019	Feb 28, 2026	Breast Cancer

Competing Products

7 competing products in Acral Lentiginous Melanoma

See all competitors

Product	Company	Stage	Hype Score
IBI310+IBI308 + IBI308 + High-dose recombinant interferon a-2B	Innovent Biologics	Phase 3	32
VX-548 + Placebo	Vertex Pharmaceuticals	Phase 2	35
BIIB074 + Placebo	Biogen	Phase 2	32
CNV1014802 + Placebo	Biogen	Phase 2	32
BIIB074	Biogen	Phase 2	24
SP-102 + Placebo	Scilex Holding	Phase 3	30
SP-102	Scilex Holding	Phase 2	25